Investing.com - Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) reported second quarter EPS of $-0.550, $0.27 worse than the analyst estimate of $-0.280. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Reviva Pharmaceuticals Holdings's stock price closed at $4.170. It is down -44.770% in the last 3 months and up 408.540% in the last 12 months.
Reviva Pharmaceuticals Holdings saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Reviva Pharmaceuticals Holdings's stock price’s past reactions to earnings here.
According to InvestingPro, Reviva Pharmaceuticals Holdings's Financial Health score is "weak performance".
Check out Reviva Pharmaceuticals Holdings's recent earnings performance, and Reviva Pharmaceuticals Holdings's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar